Chu Ambroise-Pare

Mons 7000

0 studies enrolling now · 11 studies all time

What they study most

Acute Coronary Syndrome, Antifungal Agents, Cardiovascular Disease, Endometrial Cancer, Follicular Lymphoma, Ischemic Stroke; Ischemic Attack, Transient, Non-Small Cell Lung Cancer, Paroxysmal Supraventricular Tachycardia, Rheumatoid Arthritis, Ulcerative Colitis and Crohn's Disease

Studies at this site

• A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE — Running, not enrolling
• A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome — Completed
• Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma — Running, not enrolling
• Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Running, not enrolling
• Entyvio (Vedolizumab) Long Term Safety Study — Completed
• Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT). — Stopped early
• An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis — Completed
• A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Screening Anti-Fungal Exposure in Intensive Care Units — Status unconfirmed